Menopause is a natural phase in a woman’s life, signifying the end of her reproductive years. However, a recent survey conducted across six countries shed light on the unfortunate reality of menopause discrimination in the workplace. More than a third of women reported experiencing negative impacts at work due to menopause, with some even stating that their careers had been adversely affected. These findings highlight a concerning trend that demands attention and action to create supportive and inclusive work environments for menopausal women.
The survey, encompassing approximately 13,800 women, uncovered varying degrees of discrimination across different countries. In the US and Canada, 5% of women reported facing discrimination in the workplace due to menopause, a figure that increased to 12% in Mexico. Additionally, a notable percentage of women felt that they had missed out on salary increases or promotions as a result of menopause-related issues. These statistics underscore the significance of addressing menopause discrimination on a global scale.
Vasomotor symptoms (VMS), such as hot flashes and disrupted sleep patterns, are common during menopause and can significantly impact a woman’s quality of life. Up to 80% of women experience VMS at some point during menopause, with around a third reporting severe symptoms that can persist for a decade or more. Bridget Perks, a deputy head teacher who has firsthand experience with menopause, emphasized the profound impact of these symptoms on daily life, especially in the context of a demanding career.
Recognizing the need for comprehensive support systems, Astellas Pharma sponsored the research and launched the ‘Pledge to Champion a Menopause-Inclusive Workplace’ initiative. This internal global program aims to destigmatize menopause, promote understanding, inclusivity, and support within the organization. By providing guidance, education campaigns, and training for employees and managers, Astellas seeks to create an environment where menopause is openly discussed and supported.
Katsuyoshi Sugita, Chief People Officer at Astellas, highlighted the broader implications of menopause discrimination, emphasizing its effects on productivity, talent retention, and overall workplace well-being. He stressed that organizations bear a responsibility to shift the narrative around menopause and build environments where individuals feel empowered to share their experiences. By breaking the silence surrounding menopause and fostering a culture of support, companies can create more inclusive and compassionate workplaces.
In addition to addressing workplace discrimination, it is crucial to provide effective medical interventions for menopausal symptoms. Astellas recently introduced a novel therapy, Veozah (fezolinetant), targeting VMS through neurokinin 3 (NK3) receptor antagonism. This innovative treatment offers new possibilities for managing menopausal symptoms and improving the quality of life for women experiencing menopause.
The PMi Awards 2025, formerly known as the PM Society Digital Awards, recognized outstanding achievements in the pharmaceutical industry, underscoring the importance of innovation and excellence in healthcare. Gedeon Richter’s reintroduction of a dydrogesterone-only HRT formulation in the UK market after a 17-year hiatus reflects ongoing efforts to expand treatment options for menopausal symptoms.
In the realm of pharmaceutical research and development, the integration of artificial intelligence (AI) with human intelligence is revolutionizing tracking studies and brand health monitoring. This convergence enables companies to gain real-time insights, inform strategic decisions, and establish key performance indicators (KPIs) in response to dynamic market conditions.
As the life sciences industry continues to evolve, the prominence of biosimilars grows, driven by their potential to deliver cost savings to healthcare systems. Advancements in oncology, exemplified by the development of novel treatments and therapies, offer hope to both industry stakeholders and patients alike. Discussions around cancer treatment, including the potential of allosteric tyrosine kinase inhibitors (TKIs), shed light on the ongoing efforts to enhance oncology care.
The 4th LNP Immunogenicity & Toxicity Summit and the 7th Gene Therapy Analytical Development Summit exemplify the industry’s commitment to advancing analytical capabilities and ensuring regulatory compliance for novel therapeutics and vaccines. These gatherings provide a platform for experts to exchange insights, address challenges, and drive innovation in pharmaceutical development.
In response to the evolving landscape of healthcare, companies are adapting to meet changing needs and expectations. Remedy Meds’ acquisition of a telehealth rival underscores the growing importance of digital health solutions in delivering accessible and convenient care to patients. Amidst regulatory changes and market dynamics, partnerships like Novartis’ cardiovascular collaboration with Argo demonstrate strategic alliances to drive innovation and address unmet medical needs.
While challenges persist, such as the impact of COVID-19 on healthcare policies and practices, the industry remains resilient and responsive to emerging issues. Through collaboration, innovation, and a shared commitment to improving patient outcomes, the life sciences sector continues to make significant strides in advancing healthcare globally.
Takeaways:
– Menopause discrimination in the workplace is a significant issue affecting women globally.
– Initiatives promoting menopause-inclusive workplaces are essential to support women experiencing menopausal symptoms.
– Innovation in pharmaceuticals, such as novel therapies and biosimilars, offers new treatment options for various health conditions.
– Industry events and summits play a vital role in fostering collaboration, driving advancements, and ensuring regulatory compliance in the life sciences sector.
Tags: gene therapy, regulatory, formulation
Read more on pharmaphorum.com